PURPOSE: The high comorbidity in patients with head and neck cancer (HNC) is mainly caused by the high incidence of tobacco and alcohol abuse and has direct impact on overall survival. We investigated whether HNC and its comorbidity also influence routine laboratory values and whether these values have influence on overall survival. METHODS: A retrospective cohort of 261 patients with primary squamous cell carcinoma of the oral cavity, pharynx, or larynx diagnosed between 2001 and 2006 with a complete set of pretherapeutic laboratory values was identified. The influence of standard oncological parameters, comorbidity, and each laboratory value on overall survival (OS) was investigated in univariate and multivariate analyses. RESULTS: Two-thirds of patients were active smokers and about one half reported high alcohol consumption. 40 % of patients had severe comorbidity according to Charlson comorbidity index. The most frequent laboratory pathologies were elevated C-reactive protein (CRP) values (66 %), impaired liver enzymes (30-50 %), decreased urea levels (33 %), leukocytosis (20 %), and anemia (10 %). In multivariate analysis for OS, a comorbidity index ≥5 (Hazard ratio [HR], 2.008; 95 % confidence interval [CI], 1.117-3.610; p = 0.020), high CRP level (HR, 2.469; CI, 1.414-4.310; p = 0.001), and abnormal low red-cell count (HR, 2.525; CI, 1.250-5.102; p = 0.010) were independent prognostic variables. CONCLUSIONS: Comorbidity reflected by pathologic laboratory values is a major issue in HNC patients. Several pretherapeutic laboratory values have prognostic relevance for overall survival in HNC patients.
PURPOSE: The high comorbidity in patients with head and neck cancer (HNC) is mainly caused by the high incidence of tobacco and alcohol abuse and has direct impact on overall survival. We investigated whether HNC and its comorbidity also influence routine laboratory values and whether these values have influence on overall survival. METHODS: A retrospective cohort of 261 patients with primary squamous cell carcinoma of the oral cavity, pharynx, or larynx diagnosed between 2001 and 2006 with a complete set of pretherapeutic laboratory values was identified. The influence of standard oncological parameters, comorbidity, and each laboratory value on overall survival (OS) was investigated in univariate and multivariate analyses. RESULTS: Two-thirds of patients were active smokers and about one half reported high alcohol consumption. 40 % of patients had severe comorbidity according to Charlson comorbidity index. The most frequent laboratory pathologies were elevated C-reactive protein (CRP) values (66 %), impaired liver enzymes (30-50 %), decreased urea levels (33 %), leukocytosis (20 %), and anemia (10 %). In multivariate analysis for OS, a comorbidity index ≥5 (Hazard ratio [HR], 2.008; 95 % confidence interval [CI], 1.117-3.610; p = 0.020), high CRP level (HR, 2.469; CI, 1.414-4.310; p = 0.001), and abnormal low red-cell count (HR, 2.525; CI, 1.250-5.102; p = 0.010) were independent prognostic variables. CONCLUSIONS: Comorbidity reflected by pathologic laboratory values is a major issue in HNC patients. Several pretherapeutic laboratory values have prognostic relevance for overall survival in HNC patients.
Authors: Mia M Gaudet; Andrew F Olshan; Shu-Chun Chuang; Julien Berthiller; Zuo-Feng Zhang; Jolanta Lissowska; David Zaridze; Deborah M Winn; Qingyi Wei; Renato Talamini; Neolilia Szeszenia-Dabrowska; Erich M Sturgis; Stephen M Schwartz; Peter Rudnai; Jose Eluf-Neto; Joshua Muscat; Hal Morgenstern; Ana Menezes; Elena Matos; Alexandru Bucur; Fabio Levi; Philip Lazarus; Carlo La Vecchia; Sergio Koifman; Karl Kelsey; Rolando Herrero; Richard B Hayes; Silva Franceschi; Victor Wunsch-Filho; Leticia Fernandez; Eleonora Fabianova; Alexander W Daudt; Luigino Dal Maso; Maria Paula Curado; Chu Chen; Xavier Castellsague; Simone Benhamou; Paolo Boffetta; Paul Brennan; Mia Hashibe Journal: Int J Epidemiol Date: 2010-02-01 Impact factor: 7.196
Authors: Marshall R Posner; Diane M Hershock; Cesar R Blajman; Elizabeth Mickiewicz; Eric Winquist; Vera Gorbounova; Sergei Tjulandin; Dong M Shin; Kevin Cullen; Thomas J Ervin; Barbara A Murphy; Luis E Raez; Roger B Cohen; Monica Spaulding; Roy B Tishler; Berta Roth; Rosana del Carmen Viroglio; Varagur Venkatesan; Ilya Romanov; Sanjiv Agarwala; K William Harter; Matthew Dugan; Anthony Cmelak; Arnold M Markoe; Paul W Read; Lynn Steinbrenner; A Dimitrios Colevas; Charles M Norris; Robert I Haddad Journal: N Engl J Med Date: 2007-10-25 Impact factor: 91.245
Authors: Frank R Datema; Marciano B Ferrier; Marc P van der Schroeff; Robert J Baatenburg de Jong Journal: Head Neck Date: 2010-06 Impact factor: 3.147
Authors: Sara Shoultz-Henley; Adam S Garden; Abdallah S R Mohamed; Tommy Sheu; Michael H Kroll; David I Rosenthal; G Brandon Gunn; Amos J Hayes; Chloe French; Hillary Eichelberger; Jayashree Kalpathy-Cramer; Blaine D Smith; Jack Phan; Zeina Ayoub; Stephen Y Lai; Brian Pham; Merrill Kies; Kathryn A Gold; Erich Sturgis; Clifton D Fuller Journal: Int J Cancer Date: 2015-10-09 Impact factor: 7.396
Authors: K G Oliveira; S V von Zeidler; A Z Lamas; J R V de Podestá; A Sena; E D Souza; J Lenzi; E M Lemos; S A Gouvea; N S Bissoli Journal: Braz J Med Biol Res Date: 2014-05-30 Impact factor: 2.590